The Royal Children's Hospital Melbourne
Welcome,         Profile    Billing    Logout  
 9 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inaba, Hiroto
NCT03117751: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting
2/3
790
US, RoW
Prednisone, Prednisolone, Deltasone, Meticorten, Orasone®, Liquid Pred, Pediapred®, Sterapred®, Vincristine, Vincristine sulfate, Oncovin®, VCR, LCR, Daunorubicin, Daunomycin, rubidomycin, Cerubidine®, Pegaspargase, PEG-asparaginase, PEGLA, PEG-L-asparaginase, polyethylene glycol-L-asparaginase, Oncaspar®, Erwinase®, Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi, Erwinaze^TM, Crisantaspase, Cyclophosphamide, Cytoxan®, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Mercaptopurine, 6-MP, Purinethol®, Purixan^TM, 6-mercaptopurine, Dasatinib, Sprycel®, Methotrexate, MTX, amethopterin, Trexall®, Blinatumomab, Blincyto®, Ruxolitinib, Jakafi®, Bortezomib, Velcade®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Doxorubicin, Adriamycin®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16, Clofarabine, Clolar®, Vorinostat, Zolinza®, Suberoylanilide Hydroxamic Acid, SAHA, Idarubicin, Idarubicin HCl, 4-Demethoxydaunorubicin, 4-DMD, DMDR, Idamycin PFS®, Nelarabine, Arranon®, Atriance®, Compound 506U78, Thioguanine, 6-thioguanine, Tioguanine, 2-amino-1,7-dihydro-6H-purine-6-thione, WR-1141, Tabloid®, Lanvis®, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Rylaze™, Recombinant Erwinia, Calaspargase Pegol, ASPARLAS
St. Jude Children's Research Hospital, Incyte Corporation, Amgen, Servier
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
09/26
03/28
NCT05955261: A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Recruiting
2
70
US
Venetoclax, Venclextra, ABT-99, Azacitidine, Mylosar, Vidaza, Cytarabine, Ara-C, Cytosar-U®, Gemtuzumab Ozogamicin, Mylotarg, Daunorubicin Hydrochloride, FI-6339, L-lyxo-Hexopyranoside, Fludarabine Phosphate, SH T 586, Idarubicin Hydrochloride, IMI-30, Zavedos, Mitoxantrone Hydrochloride, Neotalem, Pralifan, Novantrone, Etoposide, VP-16, Vepesid®, Gilteritinib, Xospata
St. Jude Children's Research Hospital, AbbVie
Acute Myeloid Leukemia
12/26
03/34
NCT06177067: Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
24
US
Revumenib, SNDX-5613, Venetoclax, Venclextra®, Azacitidine, VIDAZA®, 5-azacitidine, intrathecal (IT) chemotherapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Cytarabine, Ara-C, Cytosar®, Methotrexate, MTX, Trexall®
St. Jude Children's Research Hospital, Syndax Pharmaceuticals
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
01/26
07/26
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
Vickery, Brian
OUtMATCH, NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Hourglass Jul 2023 - Dec 2023 : Data readout from P3 OUtMATCH trial for food allergy
Active, not recruiting
3
471
US
Omalizumab, Xolair®, Placebo for Omalizumab, Placebo, Multi-Allergen Oral Immunotherapy, Multi-Allergen OIT, Placebo for Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen OIT, Double-Blind Placebo-Controlled Food Challenge Based Treatment, DBPCFC Based Treatment
National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc.
Peanut Allergy, Multi-food Allergy
03/23
06/25
NCT05621317: A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy

Active, not recruiting
2
90
US, RoW
PVX-108, Placebo
Aravax Pty Ltd
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
11/25
06/27
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
Khaw, Seong Lin
NCT03117751: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting
2/3
790
US, RoW
Prednisone, Prednisolone, Deltasone, Meticorten, Orasone®, Liquid Pred, Pediapred®, Sterapred®, Vincristine, Vincristine sulfate, Oncovin®, VCR, LCR, Daunorubicin, Daunomycin, rubidomycin, Cerubidine®, Pegaspargase, PEG-asparaginase, PEGLA, PEG-L-asparaginase, polyethylene glycol-L-asparaginase, Oncaspar®, Erwinase®, Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi, Erwinaze^TM, Crisantaspase, Cyclophosphamide, Cytoxan®, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Mercaptopurine, 6-MP, Purinethol®, Purixan^TM, 6-mercaptopurine, Dasatinib, Sprycel®, Methotrexate, MTX, amethopterin, Trexall®, Blinatumomab, Blincyto®, Ruxolitinib, Jakafi®, Bortezomib, Velcade®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Doxorubicin, Adriamycin®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16, Clofarabine, Clolar®, Vorinostat, Zolinza®, Suberoylanilide Hydroxamic Acid, SAHA, Idarubicin, Idarubicin HCl, 4-Demethoxydaunorubicin, 4-DMD, DMDR, Idamycin PFS®, Nelarabine, Arranon®, Atriance®, Compound 506U78, Thioguanine, 6-thioguanine, Tioguanine, 2-amino-1,7-dihydro-6H-purine-6-thione, WR-1141, Tabloid®, Lanvis®, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Rylaze™, Recombinant Erwinia, Calaspargase Pegol, ASPARLAS
St. Jude Children's Research Hospital, Incyte Corporation, Amgen, Servier
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
09/26
03/28
WUC007-03, NCT06514794: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy inT-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Recruiting
2
125
US, RoW
WU-CART-007
Wugen, Inc.
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
12/26
12/28
Troutbeck, Robyn
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Active, not recruiting
4
446
Europe, Canada, US, RoW
Faricimab
McMaster University, Hoffmann-La Roche
Diabetic Macular Edema
12/26
12/26
Perrett
NCT05621317: A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy

Active, not recruiting
2
90
US, RoW
PVX-108, Placebo
Aravax Pty Ltd
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
11/25
06/27
O'Sullivan
NCT05621317: A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy

Active, not recruiting
2
90
US, RoW
PVX-108, Placebo
Aravax Pty Ltd
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
11/25
06/27

Download Options